Comment

AusBiotech is pleased to share an opportunity for Australia’s life sciences community to hear directly from AstraZeneca’s global Search and Evaluation leaders.

The agreement brings together Imugene’s oncolytic virus CF33-CD19 (onCARlytics) and JW’s CD19-directed autologous CAR-T therapy, Carteyva, in a program that spans preclinical studies through to a Phase 1 investigator-initiated clinical trial in China.

Neurizon Therapeutics (ASX:NUZ) Chair Sergio Duchini has told shareholders the company is entering a decisive phase in its mission to bring new treatments to patients with neurodegenerative diseases, describing the past year as one of disciplined execution, strengthened governance, and meaningful scientific progress.

Proteomics International (ASX:PIQ) has secured a significant milestone in its push into the US healthcare market, with Medicare authorities setting a national reimbursement price of US$390.75 for its PromarkerD test, a predictive diagnostic for diabetic kidney disease.

Recce Pharmaceuticals (ASX:RCE) has announced promising new preclinical results demonstrating that its lead anti-infective, RECCE 327, delivered via inhalation, can significantly reduce bacterial burden in a validated mouse model of hospital- and ventilator-acquired pneumonia.

Race Oncology (ASX:RAC) has received human ethics approval to commence its HARNESS-1 Phase 1a/b clinical trial evaluating RC220, its next-generation formulation of bisantrene, in combination with AstraZeneca's TAGRISSO (osimertinib) for patients with EGFR-mutated non-small cell lung cancer.

Syntara (ASX:SNT) has taken a significant step forward in the development of its next-generation topical anti-fibrotic therapy, announcing that its lead pan-lysyl oxidase inhibitor, SNT-9465, has completed a Phase 1a clinical trial and will now progress into a Phase 1b study in patients with hypertrophic scars.

AdAlta’s (ASX:1AD) Chair has told shareholders the company has reached a pivotal point in its strategic transformation, describing 2025 as the year the business fully committed to its 'East to West' cellular immunotherapy model and positioned itself to unlock significant near-term value across its pipeline.

Tamlyn O’Connor, AusBiotech’s new Head of Global Trade and Partnerships, leads the organisation's TradeStart partnership with the Australian Trade and Investment Commission (Austrade), a collaboration designed to accelerate the global growth of Australia’s biotechnology, medical technology, pharmaceutical, and digital health companies.

A groundbreaking new biologic targeting interferon-driven autoimmune diseases has earned Professor Claudia Nold the top prize at this year’s Early-Stage Innovation Forum, held during the AusBiotech International Conference 2025 in Melbourne.

AusBiotech has appointed experienced biotechnology leader Anthea Stephenson as its new Industry Growth Program Lead, strengthening national support for early-stage Australian life science companies as they navigate the complex journey from research to commercialisation.

New South Wales Premier Chris Minns has officially opened the UNSW Health Translation Hub, a centre designed to accelerate the movement of medical research into real-world clinical practice.